The regular quantification of the BCR-ABL mRNA transcript level, evaluated by a BCR-ABL/ABL ratio every 3 months allows the determination of kinetics of CML response throughout the disease monitoring. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.